ForSight Robotics Achieves Historic First-in-Human Fully Robot-Assisted Cataract Surgery ForSight Robotics has announced a historic milestone in the evolution of eye care: the successful completion of the world’s first fully…
Avant Healthcare Professionals Expands “Dream. Become. Inspire.” Nursing Scholarship Worldwide Avant Healthcare Professionals has announced a major expansion of its flagship “Dream. Become. Inspire.” Nursing Scholarship program, extending its reach…
Zentist to Host Dental RCM Bootcamp 6.0 in Nashville, Bringing Together Industry Leaders for Advanced Revenue Cycle Insights Zentist has officially announced that its highly anticipated Dental RCM Bootcamp 6.0…
Cencora to Release Second Quarter Fiscal 2026 Results on May 6, 2026 Cencora, Inc. has officially announced the date and time for the release of its financial results for the…
Alto Neuroscience Shares Phase 2 Results for ALTO-101 and Refocuses Pipeline Strategy Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company dedicated to developing precision medicines for neuropsychiatric disorders, has released topline…
Frontier Medicines and LG Chem Forge Strategic Global Partnership for First-in-Class p53 Y220C Activator FMC-220 Frontier Medicines Corporation has entered into a landmark exclusive licensing agreement with LG Chem, Ltd.…
ENDRA Life Sciences Reports 2025 Financial Results and Highlights Strategic Progress ENDRA Life Sciences Inc a company focused on advancing thermoacoustic biomarker imaging technology, has announced its financial results for…
AHF Honors Stephen Lewis’ Global Health Legacy AIDS Healthcare Foundation (AHF) has paid tribute to the life and legacy of Stephen Lewis, a towering figure in global health diplomacy and…
AN2 Therapeutics Initiates Phase 2 Trial of Epetraborole for Difficult-to-Treat M. abscessus Lung Disease AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies using its…
PepGen Reports Positive Topline Results from Lowest-Dose (5 mg/kg) MAD Cohort in Phase 2 FREEDOM2 Study, Highlighting Safety, Splicing, and vHOT Outcomes PepGen has reported encouraging topline results from the…
Sensei Biotherapeutics Reports Full-Year 2025 Results, Advances PIKTOR Following Faeth Acquisition and $200 Million Financing Sensei Biotherapeutics, has reported its financial results for the full year ended December 31, 2025,…
Projects $170 Million EBITDA Improvement and Path to Profitability in 2026 P3 Health Partners a physician-led and patient-centered population health management organization, has released its financial results for the fourth…